Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 7,089 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: Breast Cancer, Breast Cancer Female
Interventions: Arm A: Radiotherapy Omission, Arm B: Standard Treatment; Radiation · Other
Lead sponsor: Breast Cancer Trials, Australia and New Zealand; Other
Eligibility: 50 Years and older · Female only
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2039
U.S. locations: 2
States / cities: San Francisco, California • Houston, Texas

Conditions: Breast Cancer, Cardiovascular Diseases
Interventions: Patient Navigation Program, Quality-of-Life (QOL) Assessment, Survey Administration; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Cholecalciferol; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Interventions: Biospecimen Collection, Electronic Health Record Review, Goserelin, Leuprolide, Questionnaire Administration; Procedure · Other · Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer, Resistance Training
Interventions: Online-delivered physical activity intervention., Printed, individualized resistance-based physical activity program.; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer, Lung Cancer
Interventions: Not listed
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Metastatic Breast Cancer
Interventions: Fluoxymesterone 10 mg, Anastrozole 1 mg; Drug
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer
Interventions: Injection of isotope, Axillary lymph node dissection; Procedure
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Carcinoma, Intraductal, Noninfiltrating
Interventions: Pembrolizumab, Intralesional mRNA 2752; Drug · Biological
Lead sponsor: Laura Esserman; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer
Interventions: Alpelisib, Tamoxifen, Zotatifin, Fulvestrant; Drug
Lead sponsor: Jennifer Lee Caswell-Jin; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Giredestrant-matched Placebo, Letrozole, Letrozole-matched Placebo, Palbociclib, LHRH Agonist; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 38
States / cities: Fountain Valley, California • Long Beach, California • San Leandro, California + 32 more

Conditions: Breast Cancer-related Subclinical Lymphedema
Interventions: 20-30 mmHg compression sleeve and gauntlet, Manual Lymphatic Drainage; Other
Lead sponsor: Mercy Research; Other
Eligibility: 18 Years and older · Female only
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Gastric Carcinoma, Malignant Digestive System Neoplasm, Pancreatic Carcinoma, Prostate Carcinoma
Interventions: Interview, Survey Administration; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Breast Cancer
Interventions: treated recommended; Other
Lead sponsor: Translational Drug Development; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Scottsdale, Arizona • Fairfax, Virginia

Conditions: Breast Neoplasms, Breast Diseases
Interventions: Sysmex's 5-blade lymph node cutter; Device
Lead sponsor: Sysmex America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Allentown, Pennsylvania

Conditions: Breast Cancer
Interventions: Letrozole, Everolimus, TRC105; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer, Colorectal Cancer
Interventions: Navigation, Standard of Care; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions: Cyclophosphamide, Epirubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Therapeutic Conventional Surgery, Trastuzumab; Drug · Other · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 114
States / cities: Mobile, Alabama • Castro Valley, California • Greenbrae, California + 83 more

Conditions: Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Digestive System Neoplasms, Endocrine Gland Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Breast Diseases, Renal Neoplasm, Solid Tumors
Interventions: Entinostat, Pembrolizumab; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: FDA approved GE LOGIQ E9 (LE9) ultrasound, Alpinion clinical ultrasound machine; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 266 participants
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HER2-positive Breast Cancer
Interventions: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Beverly Hills, California • San Francisco, California • Stanford, California + 9 more

Conditions: Breast Cancer
Interventions: letrozole, Blood Collection, biopsy/lumpectomy/mastectomy; Drug · Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 5
States / cities: Atlanta, Georgia • Tulsa, Oklahoma • Pittsburgh, Pennsylvania + 1 more

Conditions: Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions: PAXMAN Scalp Cooler; Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)

Patient Care Outreach, Navigation, Technology and Support 2.0

Vitamin D Supplementation in Women With DCIS and/or LCIS

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

Breast Cancer and Resistance Exercise Program

Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum

Tumor Specific Plasma DNA

Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer

Axillary Reverse Mapping

Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Subclinical Lymphedema Treatment Study

Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer

A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer

Clinical Evaluation of Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Trial of Patient Navigation-Activation

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Classification of Breast Masses Based on Visco-elastic Properties Using SAVE Method

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients